Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Most risk factors under study (i.e., hyperglycemia, unhealthy diet, lower cardiorespiratory fitness, smoking, alcohol consumption, and hypertension) were significantly associated with lower retinal sensitivity and lower RNFL thickness.
-
Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials.
-
Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01).
-
Levels of CSF Aβ42 decreased in patients with BD who had an episode during follow-up (BD-E) (N = 22) compared to patients without an episode (BD-NE) (N = 25) during follow-up (P = 0.002).
-
Three biomarkers were identified to differ among the AD stages, including neurofilament light chain (NfL; p < 0.001), fatty acid binding protein 3 (Fabp3; p < 0.001), and interleukin (IL)-10 (p = 0.033).
-
Thirty-eight (68%) patients who consented to PET imaging had PS-MCI.
-
These results suggest that prevalence of brain amyloid pathology differed, but that eligibility based on plasma was equally effective across racial and ethnic group members.
-
UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum.
-
62/100
Plasma Aβ42/40 was a robust biomarker for AD which was not affected by renal function.
-
62/100
Recent studies suggest that blood total-tau originates principally from peripheral, non-brain sources.
-
One hundred forty-six subjects (56 probable MCI-LB, 22 possible MCI-LB, 44 MCI-AD, and 24 controls) were reviewed for up to 5.7 years.
-
GFAP was associated with amyloid and tau PET in multivariable models.
-
Mass spectrometry plasma measures performed significantly better than any other measure (amyloid-β1-42/1-40: 0.817; 0.770-0.864 and amyloid-β composite: 0.820; 0.775-0.866).
-
P-tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss.
-
Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been associated with Alzheimer's disease (AD).
-
Higher amyloid beta burden was associated with increasing anxious-depressive symptoms over time in cognitively normal older individuals.
-
NfL in both serum and CSF has the potential to serve as a biomarker for clinical disease onset and has a prognostic value in genetic FTD.
-
Patients with AD have altered microvascular network in the retina (narrower retinal venules and a sparser and more tortuous retinal vessels) compared with matched nondemented controls.
-
CSF Aβ levels are altered in a subset of patients with early PD and relate to memory impairment.
-
Statins may modulate the phosphorylation of tau in humans and this effect may depend on the CNS availability of the statin.
-
At a care setting-agnostic cutoff of 0.934 pg/ml, high negative predictive value (NPV) (93.8%) and acceptable positive predictive value (PPV) (46.6%) were observed against amyloid-positron emission tomography (PET).
-
Among 191 participants (57 Black, 46 Hispanic White, 88 non-Hispanic White), age-adjusted plasma p-tau217 and p-tau217/Aβ42 performed similarly in detecting amyloid-positive individuals (≥ 25 Centiloids), regardless of race/ethnicity.
-
Amyloid status was determined by CSF in 347 patients (189 positive [54.5%]) and by PET imaging in 152 patients (66 positive [43.4%]).
-
Greater MVPA (β = -0.107; p = 0.013) and CRF (β = -0.114; p = 0.027) were associated with lower NfL, but not Aβ PET, p-tau217, Aβ1-42/1-40, or GFAP.
-
To improve clinical utility, a dual threshold approach was applied to maximize predictive values and positive likelihood ratios while minimizing the proportion of indeterminate results.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The accuracy and robustness of plasma biomarker models for amyloid PET positivity
- Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load
- Cerebral amyloid angiopathy with focal presentation-about 3 cases
- Networks of tau distribution in Alzheimer's disease
- Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort
- Developing educational materials to aid in Alzheimer's blood biomarker disclosure
- The Inflammasome Adaptor Protein ASC in Plasma as a Biomarker of Early Cognitive Changes
- Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics
- Serum brain-derived p-tau 217 and SV2A Reduce Peripheral Interference in Alzheimer’s Disease: A Multicohort Study
- Relationships of CSF biomarkers to cortical atrophy in early-onset Alzheimer's disease